Tenax Therapeutics, Inc.
TENX · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.47 | -0.10 | 0.72 | 0.05 |
| FCF Yield | -2.75% | -2.91% | -3.73% | -4.22% |
| EV / EBITDA | -11.29 | -12.32 | 0.05 | 6.35 |
| Quality | ||||
| ROIC | -11.41% | -10.37% | -34.45% | 4.75% |
| Gross Margin | 0.00% | 0.00% | 50.00% | 0.00% |
| Cash Conversion Ratio | 0.58 | 0.58 | 0.67 | 0.56 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 10.10% | -97.53% | -14.24% | -1.85% |
| Safety | ||||
| Net Debt / EBITDA | 9.72 | 10.71 | 15.13 | 24.86 |
| Interest Coverage | 0.00 | 0.00 | 68,304.37 | 731.76 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -284,130.00 | 0.00 |